To test this hypothesis, we engineered a fusion protein combining the type 2 cytokine IL‐4 with an Fc fragment (Fc–IL‐4) and assessed its effects on tumor‐infiltrating CD8+ T cells8 (Figure 1B). The gene discussed is IL4; the disease is neoplasm.